Introduction
============

Evidences show that there is an increase in psychiatric disorders particularly depression and anxiety during pregnancy \[[@B1],[@B2]\]. Although the pathogenesis is unknown, hormonal dysregulation, abnormalities in hypothalamic-pituitary-adrenal axis activity, and the contributions of genetics and epigenetics seems playing key roles in the development of perinatal mood disorders \[[@B3]\]. Women with depression during pregnancy are at increased risk for premature delivery, low birth weight, and postpartum depression \[[@B4],[@B5]\].

The estimate is that up to 13% of all pregnant women use an at least one antidepressant during pregnancy. Selective serotonin reuptake inhibitors (SSRIs) are the first-line, most frequently used antidepressants among pregnant women \[[@B3]\]. However, some studies demonstrated adverse pregnancy outcome following exposure to SSRIs. Results from our recent meta-analysis published in 2006 revealed that SSRIs do not increase the risk of major cardiovascular and minor malformations but do increase the risk of spontaneous abortion \[[@B6]\]. In the present study we have updated our previous meta-analysis by including more studies published in the recent 6 years about the effects of SSRIs on pregnancy outcomes.

Methods
=======

Data sources
------------

Scopus, PubMed, Web of Science, and Cochrane Central Register of Controlled Trials (CCRCT) were searched for studies that investigated the effect of SSRIs on pregnancy outcomes of depressive women. Data were collected for the years 1990 to 2012 (up to March). The search terms were "serotonin reuptake inhibitors" and "pregnancy", "birth outcome", or "obstetrical outcome". For PubMed, all relevant MeSH terms were used. For Web of Science and CCRCT, the same entry terms including their abbreviations were applied. The final queries were validated by manual review and matching results. The reference lists from retrieved articles were manually reviewed for finding additional applicable studies.

Study selection
---------------

All controlled studies that investigated the effect of SSRIs on pregnancy outcomes were considered. Spontaneous abortion, major malformations, minor malformations, and cardiovascular malformations were the key outcomes of interest. Major malformations are all singular and combined structural defects, syndromes, sequences, and associations. Minor malformations include small structural developmental disturbances that do not impair viability and do not need to be treated.

Studies and abstracts that were presented at meetings were also considered. Two reviewers independently examined the title and abstract of each article to eliminate duplicates, reviews, case studies, uncontrolled trials, trials did not have desired outcomes, and trials published in languages other than English. Reviewers independently extracted data on type of study, therapeutic regimens, time of exposure, and outcome measures. Disagreements were resolved by consensus.

Statistical analysis
--------------------

Data from selected studies were extracted in the form of 2×2 Tables. Included studies were weighted and pooled. The data were analyzed using StatsDirect software version 2.7.8. Odds ratio (OR) and 95% confidence intervals (95% CI) were calculated using the Mantel-Haenszel, Robins-Breslow-Greenland and Der Simonian-Laird methods. The Cochran Q test was used to test heterogeneity. In case of heterogeneity or probability of few included studies in meta-analysis, the random effects for individual and summary of effect size for weighted mean difference was applied. Funnel plot analysis was used as publication bias indicator.

Results
=======

The electronic searches yielded 3192 items; 1143 from PubMed, 67 from CCRCT, 655 from Web of Science, and 1327 from Scopus. Of these, 52 trials were scrutinized in full text and 25trials \[[@B7]-[@B31]\] were included in the analysis (Figure [1](#F1){ref-type="fig"}). Type of study, SSRI subclass, and time of exposure for each study are presented in Table [1](#T1){ref-type="table"}.

![Flow diagram of the study selection process.](2008-2231-20-75-1){#F1}

###### 

**Characteristics and results of studies included in meta**-**analysis**

  **Study**                             **Drug**                                                                           **Type**                         **Mean maternal age**   **Time of Ex**    **Spontaneous abortion**   **Major Mal**   **Cardiovascular Mal**   **Minor Mal**                                       
  ------------------------------------- ---------------------------------------------------------------------------------- -------------------------------- ----------------------- ----------------- -------------------------- --------------- ------------------------ --------------- ---------- -------------- --------- ------------
  Nordeng et al. 2012 \[[@B7]\]         Citalopram Escitalopram Paroxetine Fluoxetine Sertraline Fluvoxamine               Prospective cohort               ND                      First trimester   \-                         \-              12/462                   1550/61648      6/462      541/61648      13/462    1279/61648
  Malm et al. 2011 \[[@B8]\]            Citalopram Escitalopram Paroxetine Fluoxetine Sertraline Fluvoxamine               Retrospective cohort             29.6                    First trimester   \-                         \-              303/6976                 22305/623402    116/6976   8137/623402    \-        \-
  Colvin et al. 2011 \[[@B9]\]          Citalopram Paroxetine Fluoxetine Sertraline                                                                         30.2                    First trimester   \-                         \-              115/2701                 3834/94561      30/2701    661/94561      30/6976   737/623402
  Kornum et al. 2010 \[[@B10]\]         paroxetine fluoxetine citalopram escitalopram sertraline                           Prospective                      30.15                   First trimester   \-                         \-              \-                       \-              26/2062    1403/213712    \-        \-
  Merlob et al. 2009 \[[@B11]\]         Paroxetine Fluoxetine Citalopram Escitalopram Sertraline Fluvoxamine Venlafaxine   Prospective                      ND                      First trimester   \-                         \-              8/235                    1083/67636      8/235      1083/67636     \-        \-
  Wichman et al. 2009 \[[@B12]\]        Paroxetine Fluoxetine Citalopram Escitalopram Sertraline Venlafaxine               Retrospective cohort             ND                      Throughout        \-                         \-              \-                       \-              3/808      205/24406      \-        \-
  Einarson et al. 2009 \[[@B13]\]       Paroxetine Fluoxetine Citalopram Sertraline Fluvoxamine                            Prospective cohort               ND                      First trimester   \-                         \-              19/506                   25/928          \-         \-             \-        \-
  Diav-Citrin et al. 2008 \[[@B14]\]    Paroxetine Fluoxetine                                                              Prospective Cohort               31.5                    First trimester   \-                         \-              30/601                   34/1359         14/601     8/1359         \-        \-
  Oberlander et al. 2008 \[[@B15]\]     Paroxetine Fluoxetine Citalopram Sertraline Fluvoxamine                            Retrospective cohort             29.6                    First trimester   \-                         \-              75/2459                  3369/107320     18/2459    512/107320     \-        \-
  Einarson et al. 2008 \[[@B16]\]       Paroxetine                                                                         Retrospective cohort             ND                      Throughout        \-                         \-              \-                       \-              9/1174     9/1174         \-        \-
  Källén et al. 2007 \[[@B17]\]         Paroxetine Fluoxetine Citalopram Escitalopram Sertraline Fluvoxamine               Retrospective cohort             ND                      First trimester   \-                         \-              \-                       \-              78/6555    11367/873876   \-        \-
  Wen et al. 2006 \[[@B18]\]            Paroxetine Fluoxetine Citalopram Sertraline Fluvoxamine                            Retrospective                    ND                      Throughout        \-                         \-              20/961                   76/3861         \-         \-             35/961    133/3861
  Wogelius et al. 2006 \[[@B19]\]       ND, any SSRI                                                                       Retrospective cohort             ND                      First trimester   \-                         \-              51/1051                  5112/150780     \-         \-             \-        \-
  Vial et al. 2006 \[[@B20]\]           Paroxetine                                                                         Prospective cohort               31                      First trimester   80/683                     31/683          12/535                   10/631          3/535      3/631          1/535     1/631
  Sivojelezova et al. 2005 \[[@B21]\]   Paroxetine Fluoxetine Citalopram Sertraline                                        Prospective cohort               31.9                    First trimester   27/264                     13/132          4/223                    1/118           2/223      \-             \-        \-
  Malm et al. 2005 \[[@B22]\]           Paroxetine Fluoxetine Citalopram Sertraline Fluvoxamine                            Retrospective cohort             30                      Throughout        \-                         \-              75/1767                  62/1779         \-         \-             \-        \-
  Casper et al. 2003 \[[@B23]\]         Paroxetine Fluoxetine Sertraline Fluvoxamine                                       Prospective cohort               35.7                    Throughout        \-                         \-              1/31                     1/13            1/31       0/13           24/31     7/13
  Costei et al. 2002 \[[@B24]\]         Paroxetine                                                                         Prospective, controlled cohort   32.9                    First trimester   \-                         \-              0/27                     0/27            0/27       0/27           \-        \-
  Diav-Citrin et al. 2002 \[[@B25]\]    Paroxetine                                                                         Prospective cohort               31                      Throughout        29/236                     44/629          7/196                    12/580          \-         \-             \-        \-
  Simon et al. 2002 \[[@B26]\]          Paroxetine Fluoxetine Sertraline Fluvoxamine                                                                        ND                      Throughout        \-                         \-              12/185                   9/185           1/185      2/185          \-        \-
  Einarson et al. 2001 \[[@B27]\]       Paroxetine Fluoxetine Sertraline Fluvoxamine                                       Prospective controlled cohort    ND                      First trimester   16/150                     11/150          3/124                    1/137           1/124      1/137          \-        \-
  Kulin et al. 1998 \[[@B28]\]          Paroxetine Fluoxetine Sertraline Fluvoxamine                                       Prospective controlled cohort    31                      First trimester   30/267                     21/267          9/222                    9/235           2/222      4/235          \-        \-
  Nulman et al. 1997 \[[@B29]\]         Fluoxetine                                                                         Prospective cohort               30.5                    First trimester   \-                         \-              2/55                     2/84            2/55       2/84           \-        \-
  Chambers et al. 1996 \[[@B30]\]       Fluoxetine                                                                         Prospective cohort               31                      First trimester   23/169                     22/254          9/164                    9/226           3/164      1/226          56/97     119/153
  Pastuszak et al. 1993 \[[@B31]\]      Fluoxetine                                                                                                          ND                      First trimester   19/128                     10/128          9/28                     2/110           1/98       0/110          \-        \-

ND: not determined, SSRI: selective serotonin reuptake inhibitor.

Spontaneous abortion due to exposure to SSIRs in comparison to placebo
----------------------------------------------------------------------

The summary OR of spontaneous abortion for all included data for SSRIs in comparison to placebo in seven studies \[[@B20],[@B21],[@B25],[@B27],[@B28],[@B30],[@B31]\] was 1.87 with 95% CI= 1.5 to 2.33 (P\< 0.0001, Figure [2a](#F2){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (P= 0.3113, Figure [2b](#F2){ref-type="fig"}) and could be combined, thus the fixed effects for individual and summary for OR was applied. Regression of normalized effect vs. precision for all included studies for spontaneous abortion among SSRIs vs. placebo therapy was 3.01 (95% CI= −6.94 to 0.924, P= 0.11) and Kendall's test on standardized effect vs. variance indicated tau= −0.24, P= 0.38 (Figure [2c](#F2){ref-type="fig"}).

![**a.Individual and summary odds ratio for the outcome of"spontaneous abortion"for studies including SSRIs exposure during pregnancy.b**. Heterogeneity indicators for the outcome of "spontaneous abortion" for studies including SSRIs exposure during pregnancy. **c**. Publication bias indicators for the outcome of "spontaneous abortion" for studies including SSRIs exposure during pregnancy.](2008-2231-20-75-2){#F2}

Major malformations post exposure to SSIRs in comparison to placebo
-------------------------------------------------------------------

The summary OR of major malformations for all included data for SSRIs in comparison to placebo in twenty one studies \[[@B7]-[@B9],[@B11],[@B13]-[@B15],[@B18]-[@B31]\] was 1.272 with 95% CI = 1.098 to 1.474 (P = 0.0014, Figure [3a](#F3){ref-type="fig"}), a significant results. The Cochrane Q test for heterogeneity indicated that the studies are heterogeneous (P = 0.0198, Figure [3b](#F3){ref-type="fig"}) and could not be combined, thus the random effects for individual and summary for OR was applied. Regression of normalized effect vs. precision for all included studies for major malformations among SSRIs vs. placebo therapy was 0.75 (95% CI = −0.09 to 1.52, P = 0.08) and Kendall's test on standardized effect vs. variance indicated tau= 0.08, P = 0.66 (Figure [3c](#F3){ref-type="fig"}).

![**a.Individual and summary odds ratio for the outcome of"major malformations"for studies including SSRIs exposure during pregnancy.b**. Heterogeneity indicators for the outcome of "major malformations" for studies including SSRIs exposure during pregnancy. **c**. Publication bias indicators for the outcome of "major malformations" for studies including SSRIs exposure during pregnancy](2008-2231-20-75-3){#F3}

Cardiac malformations post exposure to SSIRs in comparison to placebo
---------------------------------------------------------------------

The summary OR of cardiac malformations for all included data for SSRIs in comparison to placebo in 19 studies \[[@B7]-[@B12],[@B14]-[@B17],[@B20],[@B23],[@B24],[@B26]-[@B31]\] was 1.192 with 95% CI= 0.39 to 3.644 (Figure [4a](#F4){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are heterogeneous (P\< 0.0001, Figure [4b](#F4){ref-type="fig"}) and could not be combined, thus the random effects for individual and summary for OR was applied. Regression of normalized effect vs. precision for all included studies for cardiac malformations among SSRIs vs. placebo therapy was 2.18 (95% CI= −2.71 to 7.06, P= 0.36) and Kendall's test on standardized effect vs. variance indicated tau= −0.41, P= 0.02 (Figure [4c](#F4){ref-type="fig"}).

![**a.Individual and summary odds ratio for the outcome of"cardiac malformations"for studies including SSRIs exposure during pregnancy.b**. Heterogeneity indicators for the outcome of "cardiac malformations" for studies including SSRIs exposure during pregnancy. **c**. Publication bias indicators for the outcome of "cardiac malformations" for studies including SSRIs exposure during pregnancy.](2008-2231-20-75-4){#F4}

Minor malformations post exposure to SSIRs in comparison to placebo
-------------------------------------------------------------------

The summary OR of minor malformations for all included data for SSRIs in comparison to placebo in six studies \[[@B7],[@B9],[@B18],[@B20],[@B23],[@B30]\] was 1.36 with 95% CI= 0.61 to 3.04 (Figure [5a](#F5){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are heterogeneous (P\< 0.0001, Figure [5b](#F5){ref-type="fig"}) and could not be combined, thus the random effects for individual and summary for OR was applied. Regression of normalized effect vs. precision for all included studies for minor malformations among SSRIs vs. placebo therapy was −0.93 (95% CI= −9.38 to 7.52, P= 0.78) and Kendall's test on standardized effect vs. variance indicated tau= −0.07, P= 0.72 (Figure [5c](#F5){ref-type="fig"}).

![**a.Individual and summary odds ratio for the outcome of"minor malformations"for studies including SSRIs exposure during pregnancy.b**. Heterogeneity indicators for the outcome of "minor malformations" for studies including SSRIs exposure during pregnancy. **c**. Publication bias indicators for the outcome of "minor malformations" for studies including SSRIs exposure during pregnancy.](2008-2231-20-75-5){#F5}

Discussion
==========

The present study was done to update our previous meta-analysis on the effects of exposure to SSRIs during pregnancy on four obstetrical outcomes including major malformations, cardiovascular malformations, minor malformations, and spontaneous abortion, to evaluate whether SSRIs increase the risk of these outcomes. The results showed that SSRIs increase the risk of spontaneous abortion and major malformations significantly but the risk of minor and cardiovascular malformations did not show significant increase. Our previous meta-analysis demonstrated only a significant increase in the risk of spontaneous abortion while in the current study the risk of major malformations was increased by SSRIs.

There are some differences between current meta-analysis and previous one. One is the number of studies included because collection of data for previous meta-analysis was up to August 2005 but for the current one was up to March 2012. In the previous meta-analysis, only 9 studies were eligible to be included while there were 25 eligible studies in the present meta-analysis. Thus the number of subjects included for each outcome is dramatically increased in the current meta-analysis. In previous meta-analysis, 2378 subjects included for spontaneous abortion whereas 4140 subjects included for this outcome in the current one; 2699 subjects for major malformations in the previous vs.1135131 in the current one; 1923 for cardiac malformation in previous vs. 1476987 in the current one; and 883 for minor malformations in the previous vs.698770 in the current one. Therefore, although the results for outcomes of spontaneous abortion, minor malformations and cardiac malformations are not apparently different from previous meta-analysis, the current results are more accurate and reliable. Interestingly, the number of major malformations in the current meta-analysis is significant while it was non-significant in the previous one. One explanation for this difference is the number of included subjects that is about 800-times higher than that of previous one. Though the risk of major malformations was statistically non-significant but it was clinically significant in previous meta-analysis. The addition of two new drugs to the list of SSRIs from the year 2008 named citalopram and escitalopram is a good reason to this new finding. Use of citalopram during pregnancy was associated with neural tube defects \[[@B8]\] and septal heart defects \[[@B32]\]. To obtain more convincing results, it is suggested to evaluate pregnancy outcomes after exposure to individual SSRIs not all SSRIs together especially for citalopram and escitalopram. However, there are two meta-analyses about the effect of paroxetine in congenital malformations \[[@B33]\]. The results of these studies have shown an increased prevalence of congenital defects and heart defects with first trimester paroxetine use.

Overall, this study demonstrates an increase risk of major malformation and spontaneous abortion following the use of SSRIs during pregnancy. This study does not show an increased risk for heart defects and minor malformations. Again we would like to emphasize to consider evaluation of SSRIs in pregnancy individually. This advice is because of different reports about congenital malformations for any of them. For example, increased risk of neural defects for citalopram \[[@B8]\] or increased prevalence of heart defects after use of paroxetine during pregnancy \[[@B34]\] can be emphasized. Of course it should not be forgotten that clinical study in pregnancy and pregnant mothers has its own limitations and that is why in most of meta-analysis studies, problem of data aggregation among included studies exists \[[@B6],[@B35]-[@B38]\] but they are inevitable limitations of such studies and therefore conducted meta-analyses.
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